Global Migraine Therapeutics Market

Migraine Therapeutics Comprehensive Study by Type (Drugs, Devices), Application (Treatment, Therapeutic agent), Type (Type 1, Type 2), Treatment (Preventive treatment, Abortive treatment) Players and Region - Global Market Outlook to 2030

Migraine Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Migraine Therapeutics
Research and development are being initiated and new programs are being launched to increase the market access for migraine therapeutics. Genetic formulations are also in the process of testing for Migraine therapeutics which are driving the market. It basically deals with the treatment of acute and chronic states of a migraine. This therapeutics can be preventive or abortive and determines the treatment of migraine. Migraine is a neurological disease which is prevalent globally and is also reported that frequent use of some medicines or overdose can also lead to a migraine. According to Migraine Research Foundation, 17.4% Women are exposed to a migraine as compared to men (6%) due to fluctuation in female reproductive hormones like estrogen and results in a migraine. Due to this fluctuation, they are found less responsive to such therapeutics.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is fragmented due to a number of key players offering various therapeutics to treat the increasing prevalence of migraine. The migraine therapeutic industry will support clients and identify new growth opportunities and strategies in the forecast period.The Players having a strong hold in the market are Eli Lilys. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Migraine Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Alder BioPharmaceuticals (United States), Allergan (Ireland), Amegen (United States), Eli Lilly and Company (United States), Teva Pharmaceuticals Industries (Israel), Amirall (Spain), AstraZeneca (United Kingdom) and Merck (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Revance Therapeutics (United States), OptiNose (United States) and RedHill Biopharma (Israel).

Segmentation Overview
AMA Research has segmented the market of Global Migraine Therapeutics market by Type (Drugs and Devices), Application (Treatment and Therapeutic agent) and Region. On the basis of Type, Drugs are dominating the market in the year 2023



On the basis of geography, the market of Migraine Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Asia Pacific region held largest market share in the year 2023. If we see Market by Type, the sub-segment i.e. Type 1 will boost the Migraine Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Preventive treatment will boost the Migraine Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing awareness programs among patients related to the treatment of migraine., Increasing the popularity of devices for the treatment of migraine, The rising popularity of devices for the treatment of migraine and Increasing unmet demands.

Market Growth Drivers:
High incidence of patients suffering from migraine, Increasing awareness about migraine therapeutics and Improvement inaccurate diagnosis for a condition like migraine.

Challenges:
Side effects of drugs of migraine and Increased preference for alternative drugs.

Restraints:
Lack of proper and undiagnosed cases of migraine, Adverse effects of drugs of migraine and Increasing preferences of alternative drugs.

Opportunities:
The increasing number of cases of migraine reported is providing opportunities for the key players to adopt new strategies in this market.

Market Leaders and their expansionary development strategies
In October 2022, Pfizer Inc. has acquired of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
In November 2023, Dr Reddy's Laboratories, a pharmaceutical company, has launched Nerivio in India. Nerivio, is a United States Food and Drug Administration (USFDA) approved wearable therapy device for drug-free management of migraine. Migraine is a global health challenge, affecting around 30% of adults


Key Target Audience
Healthcare providers, Government agencies, Distributors and Suppliers and Pharmaceutical industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Drugs
  • Devices
By Application
  • Treatment
  • Therapeutic agent
By Type
  • Type 1
  • Type 2

By Treatment
  • Preventive treatment
  • Abortive treatment

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High incidence of patients suffering from migraine
      • 3.2.2. Increasing awareness about migraine therapeutics
      • 3.2.3. Improvement inaccurate diagnosis for a condition like migraine.
    • 3.3. Market Challenges
      • 3.3.1. Side effects of drugs of migraine
      • 3.3.2. Increased preference for alternative drugs.
    • 3.4. Market Trends
      • 3.4.1. Increasing awareness programs among patients related to the treatment of migraine.
      • 3.4.2. Increasing the popularity of devices for the treatment of migraine
      • 3.4.3. The rising popularity of devices for the treatment of migraine
      • 3.4.4. Increasing unmet demands.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Migraine Therapeutics, by Type, Application, Type, Treatment and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Migraine Therapeutics (Value)
      • 5.2.1. Global Migraine Therapeutics by: Type (Value)
        • 5.2.1.1. Drugs
        • 5.2.1.2. Devices
      • 5.2.2. Global Migraine Therapeutics by: Type (Value)
        • 5.2.2.1. Type 1
        • 5.2.2.2. Type 2
      • 5.2.3. Global Migraine Therapeutics by: Application (Value)
        • 5.2.3.1. Treatment
        • 5.2.3.2. Therapeutic agent
      • 5.2.4. Global Migraine Therapeutics by: Type (Value)
        • 5.2.4.1. Drugs
        • 5.2.4.2. Devices
      • 5.2.5. Global Migraine Therapeutics by: Type (Value)
        • 5.2.5.1. Type 1
        • 5.2.5.2. Type 2
      • 5.2.6. Global Migraine Therapeutics by: Treatment (Value)
        • 5.2.6.1. Preventive treatment
        • 5.2.6.2. Abortive treatment
      • 5.2.7. Global Migraine Therapeutics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Migraine Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alder BioPharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amegen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amirall (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Migraine Therapeutics Sale, by Type, Application, Type, Treatment and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Migraine Therapeutics (Value)
      • 7.2.1. Global Migraine Therapeutics by: Type (Value)
        • 7.2.1.1. Drugs
        • 7.2.1.2. Devices
      • 7.2.2. Global Migraine Therapeutics by: Type (Value)
        • 7.2.2.1. Type 1
        • 7.2.2.2. Type 2
      • 7.2.3. Global Migraine Therapeutics by: Application (Value)
        • 7.2.3.1. Treatment
        • 7.2.3.2. Therapeutic agent
      • 7.2.4. Global Migraine Therapeutics by: Type (Value)
        • 7.2.4.1. Drugs
        • 7.2.4.2. Devices
      • 7.2.5. Global Migraine Therapeutics by: Type (Value)
        • 7.2.5.1. Type 1
        • 7.2.5.2. Type 2
      • 7.2.6. Global Migraine Therapeutics by: Treatment (Value)
        • 7.2.6.1. Preventive treatment
        • 7.2.6.2. Abortive treatment
      • 7.2.7. Global Migraine Therapeutics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Migraine Therapeutics: by Type(USD Million)
  • Table 2. Migraine Therapeutics Drugs , by Region USD Million (2018-2023)
  • Table 3. Migraine Therapeutics Devices , by Region USD Million (2018-2023)
  • Table 4. Migraine Therapeutics: by Type(USD Million)
  • Table 5. Migraine Therapeutics Type 1 , by Region USD Million (2018-2023)
  • Table 6. Migraine Therapeutics Type 2 , by Region USD Million (2018-2023)
  • Table 7. Migraine Therapeutics: by Application(USD Million)
  • Table 8. Migraine Therapeutics Treatment , by Region USD Million (2018-2023)
  • Table 9. Migraine Therapeutics Therapeutic agent , by Region USD Million (2018-2023)
  • Table 10. Migraine Therapeutics: by Type(USD Million)
  • Table 11. Migraine Therapeutics Drugs , by Region USD Million (2018-2023)
  • Table 12. Migraine Therapeutics Devices , by Region USD Million (2018-2023)
  • Table 13. Migraine Therapeutics: by Type(USD Million)
  • Table 14. Migraine Therapeutics Type 1 , by Region USD Million (2018-2023)
  • Table 15. Migraine Therapeutics Type 2 , by Region USD Million (2018-2023)
  • Table 16. Migraine Therapeutics: by Treatment(USD Million)
  • Table 17. Migraine Therapeutics Preventive treatment , by Region USD Million (2018-2023)
  • Table 18. Migraine Therapeutics Abortive treatment , by Region USD Million (2018-2023)
  • Table 19. South America Migraine Therapeutics, by Country USD Million (2018-2023)
  • Table 20. South America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 21. South America Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 22. South America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 23. South America Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 24. Brazil Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 25. Brazil Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 26. Brazil Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 27. Brazil Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 28. Argentina Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 29. Argentina Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 30. Argentina Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 31. Argentina Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 32. Rest of South America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 35. Rest of South America Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 36. Asia Pacific Migraine Therapeutics, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 40. Asia Pacific Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 41. China Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 42. China Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 43. China Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 44. China Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 45. Japan Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 46. Japan Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 47. Japan Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 48. Japan Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 49. India Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 50. India Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 51. India Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 52. India Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 53. South Korea Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 54. South Korea Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 55. South Korea Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 56. South Korea Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 57. Taiwan Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 58. Taiwan Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 59. Taiwan Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 60. Taiwan Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 61. Australia Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 62. Australia Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 63. Australia Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 64. Australia Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 69. Europe Migraine Therapeutics, by Country USD Million (2018-2023)
  • Table 70. Europe Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 71. Europe Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 72. Europe Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 73. Europe Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 74. Germany Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 75. Germany Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 76. Germany Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 77. Germany Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 78. France Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 79. France Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 80. France Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 81. France Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 82. Italy Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 83. Italy Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 84. Italy Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 85. Italy Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 86. United Kingdom Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 89. United Kingdom Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 90. Netherlands Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 91. Netherlands Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 92. Netherlands Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 93. Netherlands Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 94. Rest of Europe Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 97. Rest of Europe Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 98. MEA Migraine Therapeutics, by Country USD Million (2018-2023)
  • Table 99. MEA Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 100. MEA Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 101. MEA Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 102. MEA Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 103. Middle East Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 104. Middle East Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 105. Middle East Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 106. Middle East Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 107. Africa Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 108. Africa Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 109. Africa Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 110. Africa Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 111. North America Migraine Therapeutics, by Country USD Million (2018-2023)
  • Table 112. North America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 113. North America Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 114. North America Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 115. North America Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 116. United States Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 117. United States Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 118. United States Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 119. United States Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 120. Canada Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 121. Canada Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 122. Canada Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 123. Canada Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 124. Mexico Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 125. Mexico Migraine Therapeutics, by Application USD Million (2018-2023)
  • Table 126. Mexico Migraine Therapeutics, by Type USD Million (2018-2023)
  • Table 127. Mexico Migraine Therapeutics, by Treatment USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Migraine Therapeutics: by Type(USD Million)
  • Table 137. Migraine Therapeutics Drugs , by Region USD Million (2025-2030)
  • Table 138. Migraine Therapeutics Devices , by Region USD Million (2025-2030)
  • Table 139. Migraine Therapeutics: by Type(USD Million)
  • Table 140. Migraine Therapeutics Type 1 , by Region USD Million (2025-2030)
  • Table 141. Migraine Therapeutics Type 2 , by Region USD Million (2025-2030)
  • Table 142. Migraine Therapeutics: by Application(USD Million)
  • Table 143. Migraine Therapeutics Treatment , by Region USD Million (2025-2030)
  • Table 144. Migraine Therapeutics Therapeutic agent , by Region USD Million (2025-2030)
  • Table 145. Migraine Therapeutics: by Type(USD Million)
  • Table 146. Migraine Therapeutics Drugs , by Region USD Million (2025-2030)
  • Table 147. Migraine Therapeutics Devices , by Region USD Million (2025-2030)
  • Table 148. Migraine Therapeutics: by Type(USD Million)
  • Table 149. Migraine Therapeutics Type 1 , by Region USD Million (2025-2030)
  • Table 150. Migraine Therapeutics Type 2 , by Region USD Million (2025-2030)
  • Table 151. Migraine Therapeutics: by Treatment(USD Million)
  • Table 152. Migraine Therapeutics Preventive treatment , by Region USD Million (2025-2030)
  • Table 153. Migraine Therapeutics Abortive treatment , by Region USD Million (2025-2030)
  • Table 154. South America Migraine Therapeutics, by Country USD Million (2025-2030)
  • Table 155. South America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 156. South America Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 157. South America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 158. South America Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 159. Brazil Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 160. Brazil Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 161. Brazil Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 162. Brazil Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 163. Argentina Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 164. Argentina Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 165. Argentina Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 166. Argentina Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 167. Rest of South America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 168. Rest of South America Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 169. Rest of South America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 170. Rest of South America Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 171. Asia Pacific Migraine Therapeutics, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 173. Asia Pacific Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 174. Asia Pacific Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 175. Asia Pacific Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 176. China Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 177. China Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 178. China Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 179. China Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 180. Japan Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 181. Japan Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 182. Japan Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 183. Japan Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 184. India Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 185. India Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 186. India Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 187. India Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 188. South Korea Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 189. South Korea Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 190. South Korea Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 191. South Korea Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 192. Taiwan Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 193. Taiwan Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 194. Taiwan Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 195. Taiwan Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 196. Australia Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 197. Australia Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 198. Australia Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 199. Australia Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 204. Europe Migraine Therapeutics, by Country USD Million (2025-2030)
  • Table 205. Europe Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 206. Europe Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 207. Europe Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 208. Europe Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 209. Germany Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 210. Germany Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 211. Germany Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 212. Germany Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 213. France Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 214. France Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 215. France Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 216. France Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 217. Italy Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 218. Italy Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 219. Italy Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 220. Italy Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 221. United Kingdom Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 222. United Kingdom Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 223. United Kingdom Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 224. United Kingdom Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 225. Netherlands Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 226. Netherlands Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 227. Netherlands Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 228. Netherlands Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 229. Rest of Europe Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 230. Rest of Europe Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 231. Rest of Europe Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 232. Rest of Europe Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 233. MEA Migraine Therapeutics, by Country USD Million (2025-2030)
  • Table 234. MEA Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 235. MEA Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 236. MEA Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 237. MEA Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 238. Middle East Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 239. Middle East Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 240. Middle East Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 241. Middle East Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 242. Africa Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 243. Africa Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 244. Africa Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 245. Africa Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 246. North America Migraine Therapeutics, by Country USD Million (2025-2030)
  • Table 247. North America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 248. North America Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 249. North America Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 250. North America Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 251. United States Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 252. United States Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 253. United States Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 254. United States Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 255. Canada Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 256. Canada Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 257. Canada Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 258. Canada Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 259. Mexico Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 260. Mexico Migraine Therapeutics, by Application USD Million (2025-2030)
  • Table 261. Mexico Migraine Therapeutics, by Type USD Million (2025-2030)
  • Table 262. Mexico Migraine Therapeutics, by Treatment USD Million (2025-2030)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Migraine Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Migraine Therapeutics: by Type USD Million (2018-2023)
  • Figure 6. Global Migraine Therapeutics: by Application USD Million (2018-2023)
  • Figure 7. Global Migraine Therapeutics: by Type USD Million (2018-2023)
  • Figure 8. Global Migraine Therapeutics: by Type USD Million (2018-2023)
  • Figure 9. Global Migraine Therapeutics: by Treatment USD Million (2018-2023)
  • Figure 10. South America Migraine Therapeutics Share (%), by Country
  • Figure 11. Asia Pacific Migraine Therapeutics Share (%), by Country
  • Figure 12. Europe Migraine Therapeutics Share (%), by Country
  • Figure 13. MEA Migraine Therapeutics Share (%), by Country
  • Figure 14. North America Migraine Therapeutics Share (%), by Country
  • Figure 15. Global Migraine Therapeutics share by Players 2023 (%)
  • Figure 16. Global Migraine Therapeutics share by Players (Top 3) 2023(%)
  • Figure 17. Global Migraine Therapeutics share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Alder BioPharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 20. Alder BioPharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 21. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 23. Amegen (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amegen (United States) Revenue: by Geography 2023
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 27. Teva Pharmaceuticals Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceuticals Industries (Israel) Revenue: by Geography 2023
  • Figure 29. Amirall (Spain) Revenue, Net Income and Gross profit
  • Figure 30. Amirall (Spain) Revenue: by Geography 2023
  • Figure 31. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck (United States) Revenue: by Geography 2023
  • Figure 35. Global Migraine Therapeutics: by Type USD Million (2025-2030)
  • Figure 36. Global Migraine Therapeutics: by Type USD Million (2025-2030)
  • Figure 37. Global Migraine Therapeutics: by Application USD Million (2025-2030)
  • Figure 38. Global Migraine Therapeutics: by Type USD Million (2025-2030)
  • Figure 39. Global Migraine Therapeutics: by Type USD Million (2025-2030)
  • Figure 40. Global Migraine Therapeutics: by Treatment USD Million (2025-2030)
  • Figure 41. South America Migraine Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Migraine Therapeutics Share (%), by Country
  • Figure 43. Europe Migraine Therapeutics Share (%), by Country
  • Figure 44. MEA Migraine Therapeutics Share (%), by Country
  • Figure 45. North America Migraine Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alder BioPharmaceuticals (United States)
  • Allergan (Ireland)
  • Amegen (United States)
  • Eli Lilly and Company (United States)
  • Teva Pharmaceuticals Industries (Israel)
  • Amirall (Spain)
  • AstraZeneca (United Kingdom)
  • Merck (United States)
Additional players considered in the study are as follows:
Revance Therapeutics (United States) , OptiNose (United States) , RedHill Biopharma (Israel)
Select User Access Type

Key Highlights of Report


Apr 2024 214 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Migraine Therapeutics Market Quantitative research analysis
Global Migraine Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Alder BioPharmaceuticals (United States), Allergan (Ireland), Amegen (United States), Eli Lilly and Company (United States), Teva Pharmaceuticals Industries (Israel), Amirall (Spain), AstraZeneca (United Kingdom) and Merck (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing awareness programs among patients related to the treatment of migraine. " is seen as one of major influencing trends for Migraine Therapeutics Market during projected period 2023-2030.
The Migraine Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Migraine Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Hepatitis Drugs Comprehensive Study by Type (Interferon Alphas, Monoclonal Antibody, Nucleotide Polymerase/NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, O...
$ 3800
Biopharma Outsourcing Comprehensive Study by Application (Clinical Trials, Drug Discovery, API Development, Contract Production & Packaging, Non-Clinical Services, Others), Outsourcing Scale (Large S...
$ 3230
Bronchodilator Comprehensive Study by Type (Short-acting Bronchodilator, Long-acting Bronchodilator), Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Reactions, Others), Drug Cl...
$ 3750
Acne Vulgaris Comprehensive Study by Application (Hospitals, Clinics, Others), Therapy Type (Systemic Therapy, Harmonal Therapy, Topical Combination Therapy, Others), Type of Lesions (Non inflammator...
$ 3500
Myasthenia Gravis Comprehensive Study by Type (Congenital Hereditary, Autoimmune Disease), Application (Hospital, Medical Clinical Research Center, Others), Treatment type (Therapeutic approach, Medi...
$ 3750
Transdermal Skin Patches Comprehensive Study by Type (Drug in Adhesive, Matrix, Reservoir, Vapor, Other), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospital Ph...
$ 3450